 |
| pharmacogenomics market |
The global pharmacogenomics market is estimated to be valued at US$14,028.01 million in 2023 and is
expected to exhibit a CAGR of 11.1% over
the forecast period 2023-2030, according to a report by Coherent Market
Insights.
Market Overview:
Pharmacogenomics is the study of how a person's genes interact with drugs,
allowing physicians to develop personalized treatment plans based on an
individual's genetic makeup. It offers several advantages such as reducing
adverse drug reactions, improving drug efficacy, and optimizing treatment
outcomes. The increasing demand for personalized medicine, driven by the rising
prevalence of chronic diseases and advancements in genetic testing
technologies, is fueling the growth of the pharmacogenomics market.
Market Key Trends:
One key trend in the Pharmacogenomics
Market Size is the integration of pharmacogenomic data into electronic
health records (EHRs). This enables healthcare providers to access
patient-specific genetic information at the point of care, facilitating
evidence-based prescribing and reducing the trial-and-error approach to drug
selection. By leveraging this information, clinicians can better predict a
patient's response to medications, optimize dosages, and minimize the risk of
adverse reactions.
Porter’s Analysis
The pharmacogenomics market analyses the various factors that influence the
competitiveness and profitability of the industry using Porter's Five Forces
analysis.
1. Threat of New Entrants: The threat of new entrants in the pharmacogenomics
market is relatively low. This is mainly due to the high barriers to entry,
including the need for significant investment in research and development,
regulatory compliance, and advanced technologies. Established companies have a
strong presence and hold patents for innovative products and services, making
it difficult for new players to compete. Furthermore, the complex nature of the
industry requires specialized knowledge and expertise, limiting the entry of
new entrants.
2. Bargaining Power of Buyers: The bargaining power of buyers in the
pharmacogenomics market is moderate. While buyers have access to a wide range
of options from different companies, the critical nature of pharmacogenomics
and the specialized nature of products and services limit buyer power.
Additionally, buyers in this market rely on accuracy, reliability, and quality,
leading to stronger relationships with trusted suppliers.
3. Bargaining Power of Suppliers: The bargaining power of suppliers in the
pharmacogenomics market is high. The market heavily relies on advanced
technologies, genetic testing kits, and research tools, which are supplied by a
limited number of companies. Suppliers can exert control over pricing, terms,
and conditions, impacting the overall profitability of companies. Moreover, the
lack of alternative suppliers reduces the bargaining power of buyers.
4. Threat of New Substitutes: The threat of new substitutes in the
pharmacogenomics market is low. The unique benefits offered by
pharmacogenomics, such as personalized medicine and targeted therapies, make it
challenging for substitutes to replicate the same level of accuracy and
efficacy. As a result, the demand for pharmacogenomics remains strong with
limited alternatives.
5. Competitive Rivalry: The competitive rivalry within the pharmacogenomics
market is intense. The market is characterized by the presence of key players
such as Admera Health, Abbott Laboratories, Novartis AG, and Roche Ltd., among
others. These companies compete based on product differentiation, pricing,
research and development, and partnerships. Continuous advancements in technologies
and the introduction of new products intensify the competition within the
market.
Key Takeaways
1. The global pharmacogenomics market is expected to witness high growth,
exhibiting a CAGR of 11.1% over the
forecast period (2023-2030). The increasing adoption of personalized medicine,
advancements in genetic testing technologies, and the rising prevalence of
chronic diseases are driving market growth.
2. North America is the fastest-growing and dominating region in the
pharmacogenomics market. The presence of well-established healthcare
infrastructure, technological advancements, and increasing government
initiatives to promote precision medicine contribute to the growth in this
region. Furthermore, the rise in genetic disorders and the aging population
further drive market growth in North America.
3. Key players operating in the pharmacogenomics market include Admera Health,
Abbott Laboratories, Agilent Technologies, Novartis AG, Roche Ltd., and
Illumina, Inc., among others. These key players focus on strategic initiatives
such as partnerships, mergers and acquisitions, and product launches to
strengthen their market position and expand their product portfolios.
In conclusion, the pharmacogenomics market is poised to experience significant
growth due to factors such as increasing adoption of personalized medicine and
advancements in genetic testing technologies. Market dominance lies in the
hands of key players, who are continuously investing in research and
development and forming strategic alliances to stay ahead of the competition.
The future of pharmacogenomics holds great promise in revolutionizing precision
medicine and improving patient outcomes.
Read
More:
https://www.dailyprbulletin.com/pharmacogenomics-market-growing-demand/